The Prevalence of HIV Drug Resistance among Treatment-failure Individuals and Treatment-naïve Individuals in China: A Meta-analysis.
OBJECTIVE
To understand drug resistance prevalence among treatment-failure and treatment-naïve HIV-positive individuals in China.


METHODS
We searched five electronic databases (Wanfang, CNKI, CQVIP, SinoMed, and Pubmed) for studies of HIV drug resistance. Random-effects models were carried out to estimate the prevalence of drug resistance among treatment-failure and treatment-naïve individuals, respectively.


RESULTS
The estimated nationwide rates of HIV drug resistance to any-class drugs among treatment-failure and treatment-naïve individuals were 57% (95% CI: 49%-65%) and 3.23% (95% CI: 2.47%-4.07%), respectively. Among the drug classes, the prevalence of resistance to PIs was low (1.45%; 95% CI: 0.73%-2.33%) in treatment-failure individuals, although high rates of resistance to NNRTIs (54%; 95% CI: 45%-63%) and NRTIs (40%; 95% CI: 32%-49%) were found. Resistance to any-class drugs, NNRTIs and NRTIs manifested regional differences, but resistance to PIs did not. Positive correlations were observed between resistance to NNRTIs and NRTIs among treatment-failure and treatment-naïve individuals, respectively.


CONCLUSIONS
The prevalence of HIV drug resistance to NNRTIs and NRTIs among treatment-failure individuals was high. In contrast, the prevalence of drug resistance among treatment-naïve individuals was low. The epidemics of drug resistance matched current treatment strategies and interventions in China. Surveillance for HIV drug resistance is necessary to assess the sustainability and durability of current treatment regimens.
National Center for AIDS/STD Control and Prevention, China Center for Disease and Prevention, Beijing 102206, China; School of Agroforestry & Medicine, the Open University of China, Beijing 100039, China.
Jing
J
Wu
National Center for AIDS/STD Control and Prevention, China Center for Disease and Prevention, Beijing 102206, China.
Jessie
J
Norris
National Center for AIDS/STD Control and Prevention, China Center for Disease and Prevention, Beijing 102206, China.
Hui Xin
HX
Liu
National Center for AIDS/STD Control and Prevention, China Center for Disease and Prevention, Beijing 102206, China.
Zheng
Z
Li
National Center for AIDS/STD Control and Prevention, China Center for Disease and Prevention, Beijing 102206, China.
Ying Ying
YY
Su
National Center for AIDS/STD Control and Prevention, China Center for Disease and Prevention, Beijing 102206, China.
Lin
L
Zhu
National Center for AIDS/STD Control and Prevention, China Center for Disease and Prevention, Beijing 102206, China.
Ning
N
Wang
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002681:China; D024882:Drug Resistance, Viral / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology*; D006801:Humans; D015995:Prevalence; D016032:Randomized Controlled Trials as Topic; D013997:Time Factors; D017211:Treatment Failure
D019380:Anti-HIV Agents
China; Drug resistance; HIV; Meta-analysis